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Brain Microbiota in Huntington’s
Disease Patients
Ruth Alonso†, Diana Pisa† and Luis Carrasco*
Centro de Biología Molecular “Severo Ochoa” (CSIC-UAM), Universidad Autónoma de Madrid, Madrid, Spain
One of the most important challenges facing medical science is to better understand
the cause of neuronal pathology in neurodegenerative diseases. Such is the case for
Huntington’s disease (HD), a genetic disorder primarily caused by a triplet expansion in
the Huntingtin gene (HTT ). Although aberrant HTT is expressed from embryogenesis, it
remains puzzling as to why the onset of disease symptoms manifest only after several
decades of life. In the present study, we investigated the possibility of microbial infection
in brain tissue from patients with HD, reasoning that perhaps mutated HTT could be
deleterious for immune cells and neural tissue, and could facilitate microbial colonization.
Using immunohistochemistry approaches, we observed a variety of fungal structures in
the striatum and frontal cortex of seven HD patients. Some of these fungi were found
in close proximity to the nucleus, or even as intranuclear inclusions. Identification of the
fungal species was accomplished by next-generation sequencing (NGS). Interestingly,
some genera, such as Ramularia, appeared unique to HD patients, and have not been
previously described in other neurodegenerative diseases. Several bacterial species
were also identified both by PCR and NGS. Notably, a curved and filamentous structure
that immunoreacts with anti-bacterial antibodies was characteristic of HD brains and
has not been previously observed in brain tissue from neurodegenerative patients.
Prevalent bacterial genera included Pseudomonas, Acinetobacter, and Burkholderia.
Collectively, our results represent the first attempt to identify the brain microbiota in
HD. Our observations suggest that microbial colonization may be a risk factor for HD
and might explain why the onset of the disease appears after several decades of life.
Importantly, they may open a new field of investigation and could help in the design of
new therapeutic strategies for this devastating disorder.
Keywords: Huntington’s disease, neurodegenerative diseases, polymicrobial infections, endomycosomes, fungal
infection, next generation sequencing
INTRODUCTION
Huntington’s disease (HD) is a heritable neurodegenerative disease with autosomal dominance
(Caron et al., 2018; Testa and Jankovic, 2019) that is characterized by degeneration of neurons in
specific brain regions. Its incidence fluctuates between different populations, being higher in people
of Western European descent, with the exception of some ethnic groups in Iberoamerica. HD has an
estimated prevalence of 5–12 per 100,000 persons in Europe and 0.1–2 per 100,000 persons of Asian
and African descent (Paradisi et al., 2008; Pringsheim et al., 2012; Apolinario et al., 2017; Paz et al.,
2017). Disease symptoms include motor alterations, cognitive decline and psychiatric disorders
that can progress to dementia (Jimenez-Sanchez et al., 2017). Choreic movements are typical in the
majority of patients, together with gait disturbances, rigidity, behavioral changes and depression
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(Caron et al., 2018). The disease is usually diagnosed when motor
problems are apparent, typically between 35 and 55 years of age,
although prodromal symptoms may occur 10–15 years before
diagnosis (Dayalu and Albin, 2015). Degeneration of neurons
in the caudate and putamen and in the cerebral cortex is the
primary pathologic hallmark of HD (Waldvogel et al., 2015). In
addition, widespread atrophy is common, leading to a significant
reduction in the brain volume, and affecting several regions of
the central nervous system (CNS), including the subthalamic
nucleus, thalamus, hypothalamus, globus pallidus, hippocampus,
and substantia nigra (Caron et al., 2018).
A breakthrough in HD research came in 1983 with the
discovery of a genetic marker of the disease near the tip of the
short arm of chromosome 4 (Gusella et al., 1983), and 10 years
later a triplet expansion repeat in the novel gene Huntingtin
(HTT) was mapped as the causal mutation for HD (MacDonald
et al., 1993; Holmans et al., 2017). Expansion of the CAG triplet
(encoding for glutamine) can be variable (greater than 40 times
in the mutated gene), which leads to the synthesis of a long
polyglutamine (polyQ) tract at the amino terminus of the protein
Huntingtin. In normal subjects the CAG repeat length can vary
between 7 and 26, and CAG repeats in the range 27–35 usually
does not confer the disease phenotype, but these individuals are
prone to CAG repeat instability and the consequent probability
of having a child with an allele in the pathogenic CAG range
(Semaka et al., 2013; Kay et al., 2018). An expansion in one
allele of 36–39 repeats confers risk for HD, but symptoms may
not develop. In fact, elderly subjects with CAG repeats in this
range without HD symptoms are common (Kay et al., 2016).
CAG repeat expansion beyond 40 results in full penetrance of
the disease, which will manifest during lifetime (Holmans et al.,
2017). In this regard, very long triplet repeats (usually >60)
can lead to a juvenile onset of HD. Accordingly, there is an
inverse correlation between the length of the triplet repeats and
the age at which the first symptoms of HD appear. Thus far,
there is no therapy to prevent or to modify the progression
of HD and pharmacological treatment is aimed at managing
the symptoms of the disease (Dickey and La Spada, 2018).
Nevertheless, a number of new strategies are being explored to
block the synthesis of the mutated Huntingtin, for example, using
small interfering RNAs or antisense oligonucleotides (Kim and
Kim, 2014; Singh et al., 2016; Lane et al., 2018).
Huntingtin is a large protein of 359 kDa that is subject
to a number of post-translational modifications, including
phosphorylation, acetylation, palmitoylation, among others
(Saudou and Humbert, 2016), and contains several domains
that can interact with other macromolecules. In this respect,
Huntingtin is considered a scaffolding protein that may act as
a platform for other proteins, and is capable of modulating a
variety of cellular functions, including transcription, vesicular
trafficking, autophagy, cell division, among other functions
(Saudou and Humbert, 2016). Huntingtin is necessary for early
development as the knock-out for HTT is embryonic lethal in
mice (White et al., 1997; Reiner et al., 2001). Also, HTT is
ubiquitously expressed in many tissues, and the presence of
the mutated protein could affect normal physiological functions,
particularly in CNS tissues and the immune system. It is believed
that mutated Huntingtin is more prone to proteolytic cleavage,
and can generate an amino fragment with toxic properties
(Ratovitski et al., 2009; Tebbenkamp et al., 2012), but it remains
controversial whether the formation of mutated Huntingtin
aggregates or its moieties is detrimental or beneficial for cell
survival (Saudou and Humbert, 2016). It is plausible that these
aggregates sequester the deleterious soluble Huntingtin bearing
the long polyQ tract, and thus improves cellular functions and
survival. Nevertheless, the accepted hypothesis in HD pathology
is that the synthesis of mutated Huntingtin may lead to cell
death, and thus to the destruction of neurons, particularly in
the striatum and the cortex, although other regions in the CNS
and other tissues can be affected. It remains puzzling as to why
the pathological symptoms of HD manifest after decades of HTT
expression, and also why the CNS is especially vulnerable while
other tissues that express HTT may be less affected.
An emerging field of research in neurodegenerative diseases is
the link between the gut microbiota and the CNS (Forbes et al.,
2018; Ma et al., 2019; Roy Sarkar and Banerjee, 2019). Although
some microbial infections have been studied as potential risk
factors in a variety of neurodegenerative diseases (Alonso et al.,
2015, 2017b, 2018b; Pisa et al., 2015b, 2017; Carrasco et al.,
2017), to our knowledge, no studies have analyzed the potential
involvement of microorganisms as modulators of the severity
of HD. Several arguments support such an analysis in HD: (1)
HD is associated with neuroinflammation, with the consequent
increase in cytokine levels and microglia activation (Crotti and
Glass, 2015; Rocha et al., 2016), which also occurs after infection;
(2) synthesis of amyloid is augmented in HD, as occurs in
other neurodegenerative diseases such as Alzheimer’s disease and
amyotrophic lateral sclerosis (Haass and Selkoe, 2007; Shao et al.,
2017). Amyloid peptide has anti-microbial activity, stimulates
the innate immune system, and its synthesis is believed to be
triggered by microbial infections (Soscia et al., 2010; Kumar
et al., 2016); (3) corpora amylacea (CA) can be found in HD
brains, as occurs with other neurodegenerative disorders (Pisa
et al., 2016a). We recently advanced the idea that CA could
also be a response to microbial infections, as these bodies can
collect/scavenge microbial debris (Pisa et al., 2018); (4) the
fungi and bacteria present in the CNS of patients with several
neurodegenerative diseases, but not in HD patients, have been
identified and analyzed in detail in the last few years (Pisa et al.,
2015a, 2017; Alonso et al., 2017a, 2018a).
Based on this information, we considered that it would be
interesting to compare the brain microbiota of these diseases
with that of patients with HD. In principle, it could be possible
that the modifications in cell functioning by the expression of
mutated Huntingtin could influence the microbial colonization
of the CNS. Thus, the present study aimed to comprehensively
test for potential fungi and bacteria in the CNS of HD patients.
MATERIALS AND METHODS
Brain Samples From HD Patients
Brain paraffin sections and frozen tissue were obtained from
seven patients diagnosed with HD. Samples were obtained from
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two regions: the striatum and the frontal cortex (FC). The age
and gender of each patient are listed in Supplementary Table 1.
Based on the grade of lesions found in the striatum in the
different HD patients they were classified from grade 0 to grade
IV (Supplementary Table 1; Vonsattel et al., 1985). The Banco
de Tejidos CIEN, Madrid, supplied the samples and they were
analyzed anonymously. All brain samples were provided by the
same laboratory. All of them were processed according to a
common postmortem protocol followed by Banco de Tejidos
CIEN. Briefly, rapid neuropathological autopsy was performed
upon call by the donor’s proxies (mean postmortem interval,
4.5 h). Immediately after extraction, the right half of the brain was
sliced and frozen at –80◦C. The left half was fixed by immersion
in phosphate-buffered 4% formaldehyde for at least 3 weeks.
A full neuropathological study was performed in the left half
brain after fixation. Neuropathological diagnosis and staging
of all disease entities was performed according to consensus
criteria. Samples from the frozen tissue were obtained with sterile
instruments taking all measures to avoid contamination in a
laminar flow hood. Sample transfer was carried out according
to national regulations concerning research on human biological
samples and written informed consent was obtained in all
cases. The study was approved by the ethic committee of the
Universidad Autónoma de Madrid (Ref. number CEI-60-1066).
To avoid contamination, the frozen tissue was handled with
sterile instruments in a laminar flow hood.
Antibodies Employed in This Work
The following rabbit polyclonal antibodies used in the present
study have been described previously (Pisa et al., 2015a, 2016a,b):
against Candida albicans (used at 1:100 dilution), Candida
glabrata (1:500 dilution), Syncephalastrum racemosum (1:100
dilution), Penicillium notatum (1:100 dilution), Phoma betae
(1:100 dilution), and against purified fungal enolase (1:50
dilution). A rabbit polyclonal antibody against fungal chitin
(1:50 dilution) was generously provided by Dr. M.N. Horst
(Mercer University, Macon, GA, United States). The remaining
antibodies employed were purchased from commercial vendors:
rabbit polyclonal antibody against Borrelia burgdorferi (Genetex,
Irvine, CA, United States) used at 1:50 dilution; mouse
monoclonal antibody against B. burgdorferi (Abcam, Cambridge,
United Kingdom) used at 1:10 dilution; mouse peptidoglycan
monoclonal antibody (Thermo Fisher Scientific, Waltham,
MA, United States) used at 1:20 dilution; and a rabbit
polyclonal antibody against Chlamydophila pneumoniae, which
immunoreacts with the major outer porin (Biorbyt, Cambridge,
United Kingdom) used at 1:20 dilution.
Analysis of CNS Sections From HD
Patients by Immunohistochemistry
Standard techniques were used for paraffin embedding and
sectioning of CNS tissue. Protocols for immunohistochemical
analysis have been described (Pisa et al., 2016b). Most of
the images were obtained with a Zeiss LSM710 confocal laser
scanning microscope equipped with the upright Axio Imager.M2
stand (Zeiss), running ZEN 2010 software, or with a Zeiss
LSM800 confocal laser-scanning microscope equipped with an
Axio Observer (Zeiss) inverted microscope and running Zen Blue
2.3 software. Images were deconvoluted using Huygens software
(4.2.2 p0) and visualized with ImageJ (NIH).
DNA Extraction From CNS Tissue
DNA was extracted from frozen tissue obtained from striatum
and FC regions of seven HD patients, as described previously
(Alonso et al., 2017a).
Nested PCR Assay
To prevent PCR contamination, we used separate rooms and
glassware supplies for PCR set-up and products. We also
used aliquoted reagents, positive-displacement pipettes, aerosol-
resistant tips and several negative controls. To assay for bacterial
DNA, we used nested PCR with several primer pairs as described
(Alonso et al., 2017a), which amplify a region between the V3 and
V4 variable region of the prokaryotic 16S rRNA gene. In the first
PCR, 4 µl (5–10 ng) of DNA was denatured at 95◦C for 5 min,
followed by 35 cycles of 1 min at 94◦C, 1 min at 56◦C, and 3 min
at 72◦C, using primers 27F and 1492R. The second PCR was
performed using 2 µl of the product obtained in the first PCR
with forward V3 and reverse V4 internal primers, for 30 cycles of
1 min at 94◦C, 1 min at 55◦C, and 3 min at 72◦C.
In addition, the intergenic spacer (IGS) region between rRNA
genes of the prokaryotic genome was amplified using the primers
1406 (F)/559 (R) and 1492 (F)/242 (R) in the first and second
round PCR, respectively. The first PCR was carried out with 4 µl
(5–10 ng) of DNA denatured at 95◦C for 5 min, followed by 45
cycles of 1 min at 94◦C, 1 min at 55◦C, and 3 min at 72◦C. The
second PCR was performed using 2 µl of the product obtained in
the first PCR, for 35 cycles of 1 min at 94◦C, 1 min at 57◦C, and
3 min at 72◦C. Some PCR products were sequenced by Macrogen
Inc. (Seoul, South Korea). The sequences have been submitted
to the European Nucleotide Archive with the access numbers
ERZ964645. The Borrelia spp. flagellin gene was amplified as
described previously (Pisa et al., 2017). The CAG triplets in the
HTT gene were tested using the primers described by Yoon
et al. (2003). We also analyzed the hexanucleotide expansion
repeat in the C9Orf72 gene in the different samples, as described
previously (Alonso et al., 2019).
Next-Generation Sequencing
We used a metagenomics next-generation sequencing (NGS)
protocol (Illumina platform) to amplify the ITS1 region of fungi
and the 16S rRNA gene of bacteria. This analysis was performed
by the Genomics Unit at the Scientific Park of Madrid. Quality
analyses were performed over reads using FastQC software1. All
sequences have been submitted to European Genome-phenome
Archive with the accession number EGAS00001003678.
For fungal DNA, the region between the internal 1 primer pair
was amplified with specific primers joined to linker sequences in
a first round of PCR (specific product of∼300 nt). A second PCR
was performed on this product using fusion primers containing
Illumina and linker sequences. For bacterial DNA, primers were
1http://www.bioinformatics.babraham.ac.uk/projects/fastqc/
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designed to amplify the region between V3 and V4 of 16S rDNA
gene. These primers were joined to linker sequences in a first
round of PCR (specific product of ∼400 nt). A second PCR
was performed on this product using fusion primers containing
Illumina and linker sequences. PCR products were sequenced on
a MiSeq sequencing platform (Illumina).
Computational Analysis
The adapters from the sequences were deleted using Cutadapt
and all sequences with a length shorter than 35 bp were discarded.
A minimum read length of 35 bases was set due to the wide range
of amplicon lengths (from 35 to 301) with an average of 267 and
256 pb in ITS and 16S samples, respectively. The QIIME2 software
pipeline was used for metagenomics analysis (Caporaso et al.,
2010) including the following steps: quality filtering, clustering
sequences to define operational taxonomic unit (OTU), obtaining
representative sequences and aligning them against the reference
database in order to perform the taxonomic assignment,
phylogenetic reconstruction, and diversity analyses. To define
the OTUs, the QIIME pick_open_reference_otus.py workflow was
used with an identity percentage of 97 and 94% in fungi and
bacteria, respectively. Regarding the fungal analysis according to
the taxonomical classification (species level), we found that on
average 42% of the matches corresponded to “uncultured fungus
blast” hit. For this reason, an additional standard Blast search
analysis was performed. All efforts have been made to avoid
contamination during the handling of samples. In fact, in the PCR
assays, a control without DNA indicated that it was clean without
any apparent DNA fragment, suggesting that no environmental
contamination occurred. However, since these negative controls
were not included in the DNA sequencing runs, the possibility
that some OTUs found are due to contamination can not be
completely discarded.
Principal Component Analysis
The β-diversity parameter (community structure), which gives
a between-sample diversity comparison, and core diversity
analyses, was performed with QIIME together with a Principal
Coordinates Analysis (PCoA) with Bray-Curtis distances. The
3D plot model of the PCA was made with the scatter plot
3D package in R.
RESULTS
Analysis of the CAG Expansion in HTT
and the Hexanucleotide Repeat in
C9Orf72
Since the underlying genetic defect in HD is the presence of an
expanded CAG repeat in HTT, we tested for this in the seven
patients studied in this work using nested PCR (Yoon et al.,
2003). Gel electrophoresis analysis of the PCR products revealed
the presence of two major DNA fragments for each patient: one
of a lower size corresponding to the normal allele and one of a
2http://qiime.org/
higher size corresponding to the mutated allele (Supplementary
Figure 1, panel A). After sequencing the PCR products, the
number of CAG repeats in each patient in both alleles was
determined (Supplementary Table 2). The highest expansion
corresponded to 40 CAG repeats in patient HD6. The expansion
varied from 35 to 39 repeats (HD1, HD3–HD5) in other patients,
and was within normal limits (23 repeats) in patient HD2. In
patient HD7, we found a repeat of 17 CAG triplets followed by
17 non-CAG codons and then a repeat of 7 additional CAGs
(see sequence in Supplementary Table 2). The number of CAG
triplets in the normal allele from the seven HD patients ranged
from 7 to 25. The finding that some patients classified as HD
according to their clinical symptoms did not have an abnormal
expansion repeat has been reported previously (Mariani et al.,
2016; Bourinaris and Houlden, 2018).
The C9Orf72 hexanucleotide expansion repeat has been
associated with frontotemporal degeneration and amyotrophic
lateral sclerosis spectrum disorders (van der Meer et al.,
2015). It is also indicated as a possible contributor to several
neurodegenerative diseases, including HD. Indeed, patients who
presented with an HD-like phenotype and tested negative for
pathogenic expansions in HTT have been analyzed in this respect
(Hensman Moss et al., 2014; Koutsis et al., 2015; Bourinaris
and Houlden, 2018), with frequencies of the hexanucleotide
expansion ranging from 1.75 to 5%. Thus, to complement
our results on the expansion repeat in HTT, we performed
a direct PCR assay to analyze the hexanucleotide expansion
in C9Orf72 of the seven HD patients (Alonso et al., 2019).
One major DNA fragment for each patient was obtained after
PCR amplification (Supplementary Figure 1, panel B), which
was extracted from the agarose gel and sequenced. Our results
indicated that in all cases, only three hexanucleotide repeats were
obtained (Supplementary Table 2). This number is well below
the threshold of 30 repeats believed to be pathogenic (Cleary
et al., 2016). In conclusion, none of the seven HD patients
exhibited a pathogenic expansion repeat in C9Orf72, and two
of them (HD2 and HD7) had a CAG repeat in HTT within
the normal limits, although patient HD7 contained an abnormal
sequence in this region.
Detection of Fungal Structures in Brain
Sections From Huntington’s Disease
Patients
We first tested for the presence of fungi in HD brains
using paraffin sections of striatum tissue from four HD
patients (patients HD4–HD7; grades III and IV). To this
end, immunofluorescence analysis was performed using
three different rabbit polyclonal anti-fungal antibodies, anti-
C. albicans, anti-C. glabrata and anti-P. notatum (green), and
sections were counterstained with DAPI to mark nuclei (blue).
As shown in Figure 1, some hyphal, mycelial and rounded
forms were positively stained (green) usually close to the
neural cell nucleus (panels HD4 and HD5 of C. albicans and
C. glabrata antibodies), or even apparently in the interior of
the nucleus (panels HD6 of C. albicans and C. glabrata, and
HD7 of C. glabrata and P. notatum antibodies). Of note, these
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FIGURE 1 | Immunohistochemistry of striatum sections from Huntington’s disease patients using a battery of antifungal antibodies. The striatum CNS region of four
HD patients (HD4–HD7) was processed for immunohistochemistry as described in section “Materials and Methods.” Paraffin sections were immunostained with
rabbit polyclonal antibodies against C. albicans, C. glabrata, and P. notatum (green). Nuclei were stained with DAPI (blue). Scale bar: 5 µm.
rabbit polyclonal anti-fungal antibodies are not specific for one
fungal species and they can cross-react with a variety of fungi
(Pisa et al., 2017).
Further evidence on the fungal origin of these structures
was obtained using two additional rabbit polyclonal antibodies
raised against purified fungal components: the polysaccharide
chitin, a specific component of the fungal cell wall (Walker
et al., 1990, 1991), and purified fungal enolase (Pisa et al.,
2016b). Both antibodies immunoreacted with yeast-like cells
in the striatum sections from the four patients analyzed
(Supplementary Figure 2). As before, some of these rounded
fungal cells were in close proximity to the cell nucleus. Of note,
the chitin and enolase anti-fungal antibodies do not cross-react
with human cells. Overall, the use of this panel of anti-fungal
antibodies highlights the presence of fungal cells with different
sizes and morphologies, perhaps reflecting a variety of fungal
species in brain tissue.
To broaden this analysis, brain sections from the FC and
striatum from seven patients (HD1–HD7; grades I–IV) were
examined using the anti-C. albicans antibody or a rabbit
polyclonal antibody against S. racemosum (Figure 2). Consistent
with the previous findings, several yeast-like cells were detected
(green) and, in some instances, they were also positive for DAPI,
indicating the presence of the fungal nucleus (Figure 2, panels
A: HD3 ST, HD4 FC, HD6 ST, HD6 FC; panels B: HD2 FC,
HD3 FC, HD4 FC, and HD5 FC). The size of some of these
yeast-like cells was 4–7 µm, and showed an also showed a
morphology different from that observed with the anti-chitin
antibody. The different sizes of the fungal cells detected with
each antibody may indicate the presence of a variety of species,
which are preferentially recognized by each antibody. Figure 2
(panel B: HD5 FC) illustrates a sporulating yeast cell in which the
nucleus is stained with DAPI (blue). Mycelial material was also
evident, further demonstrating the presence of fungal infection
(Figure 2, panels A: HD2 ST and HD7 FC; and panels B: HD2
ST and HD4 ST). These fungal structures were found both in
FC and striatum sections. Altogether, these findings indicate
that hyphal and yeast-like cells can be identified using a variety
of anti-fungal antibodies in brain sections from the seven HD
patients analyzed.
Of note, our attention was drawn to a group of elongated cells
of about 1 µm in FC sections of patient HD5 (Figure 3). These
yeast-like cells were immunopositive for C. albicans, supporting
the idea that they are fungal in origin. Interestingly, this type of
cell grouping was not observed in the other HD patients studied
in this work, and it suggests that each HD patient might be
colonized by different fungal species (see below).
To further assess the intracellular location of some of these
fungal structures, orthogonal projections and 3D analyses were
carried out (Figure 4). These intracellularly trapped fungi,
known as endomycosomes, have also been observed in CNS
tissue from patients with other neurodegenerative diseases
(Pisa et al., 2015a; Alonso et al., 2017a). It was clearly
evident that indeed some of these structures immunolabeled
with anti-C. albicans antibodies (green) had projections to
the nucleus, supporting the concept that the neural cells
were infected when they were alive. Intracellularly located
fungi positive for a range of anti-fungal antibodies are shown
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FIGURE 2 | Immunohistochemistry of brain sections from seven Huntington’s disease patients using anti-C. albicans and anti-S. racemosum antibodies. Two CNS
regions (striatum, ST and frontal cortex, FC) from seven HD patients (HD1–HD7) were processed for immunohistochemistry analysis. Paraffin sections were
immunostained with rabbit polyclonal antibodies against C. albicans (A) or S. racemosum (B) (green). Nuclei were stained with DAPI (blue). Scale bar: 5 µm.
in Supplementary Movies 1–5, demonstrating their close
connection with the nucleus.
Corpora amylacea in Huntington’s
Disease
Previous studies from our laboratory have found fungal
antigens in CA in patients with different neurodegenerative
diseases (Pisa et al., 2016a, 2017; Alonso et al., 2018b). Using
both immunohistochemistry and proteomic analyses, we have
unequivocally identified fungal proteins in purified CA from
patients with Alzheimer’s disease (Pisa et al., 2018). Although CA
were described many years ago in the striatum from HD patients
(Averback, 1981), to our knowledge very little is known about CA
in HD. As shown in Figure 5, CA varying in size (10–40 µm)
could be clearly identified in the striatum of the HD patients
examined in this work, and these bodies immunoreacted with
a variety of anti-fungal antibodies. In accord with our previous
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FIGURE 3 | Fungal structures in the frontal cortex region from one
Huntington’s disease patient (HD5) analyzed by immunohistochemistry.
Immunohistochemistry analysis was carried out using polyclonal antibody
against C. albicans (green). Nuclei were stained with DAPI (blue). Scale bar:
5 µm.
FIGURE 4 | Orthogonal projection and 3D analysis of intracellular microbial
structures. Immunohistochemistry was carried out as described in section
“Materials and Methods.” Orthogonal projections (A,B) and different stacks
from a 3D image (C,D) (see also Supplementary Movies 1, 2) from the
striatum of HD6 patient. Panels (A,C) show the same cell that appear in
panels (B,D), respectively. Samples were immunostained with an
anti-C. albicans antibody (green). Nuclei were stained with DAPI (blue). All
scale bars: 5 µm.
findings, the fungal antigens were mainly located in the envelope
that surrounds a central portion of these spherical bodies.
In some instances, immunoreactivity with the anti-P. notatum
antibody was also found in the internal portion of CA (Figure 5,
panel C). Immunoreactivity was also observed for antibodies
against C. albicans, P. notatum, P. betae, chitin and enolase. These
findings support the notion that fungal antigens are recruited,
together with cellular debris, during the formation of CA. Of
note, CA bodies were more easily identified in grades III–IV HD
patients. We have previously proposed that CA may represent
a response to microbial infections in the CNS of patients with
neurodegenerative diseases (Pisa et al., 2016a, 2018). Since CA are
built up during several months or even years, it seems plausible to
believe that fungal infections are present during this time period
long before death.
Identification of Fungal Species in
Huntington’s Disease Brains
We next used NGS to precisely determine the fungal species
present in HD brains. Extracted DNA from frozen tissue of
both FC and striatum from patients HD1–HD7 was employed
to amplify the fungal ITS1 located between the 18S and the 5.8S
rRNA genes (as detailed in Materials and Methods). NGS was
carried out using the Illumina platform, as indicated. The number
of read sequences obtained for each sample varied between
1,18,143 and 2,13,301. Bioinformatic analyses of these sequences
revealed a variety of fungal species, as detailed in Supplementary
Table 3, which lists the fungal species above 1%. The fungal
phyla order and genera in the two brain regions of the seven
patients are shown in Figure 6 and the most prevalent fungal
genera are listed in Table 1. These genera included Candida,
Davidiella, Malassezia, Rhodotorula, and Ramularia. Of note,
with the single exception of the genus Ramularia, these genera
were also identified in brain tissue from other neurodegenerative
diseases (Alonso et al., 2015, 2017a, 2018a; Pisa et al., 2018). It
is possible that the tropism of Ramularia for HD patients makes
this fungus more prevalent.
Notably, PCA of the NGS data indicated that the distribution
of these genera was similar between the FC and striatum regions
(Figure 7, panel A). Interestingly, the distribution of fungal
genera between patients with HD and those with Parkinson’s
disease was significantly different (Figure 7, panel B). Overall,
these results show that there are no major differences between
the fungi present in the FC and striatum region in HD patients,
whereas striking differences are evident between the fungi
detected between HD and Parkinson’s disease. This finding is
consistent with the notion that the mycoses in these patients with
two different motor diseases differ.
Analysis of Prokaryotic Structures in
Huntington’s Disease Brains
We next tested for the presence of bacteria in HD brain
samples by immunohistochemistry using a battery of anti-
bacterial antibodies. We failed to find any robust signal using
the three commercial antibodies (see section “Materials and
Methods”), with a rabbit polyclonal antibody and a mouse
monoclonal antibody against B. burgdorferi. Likewise, no evident
signal was found with a mouse monoclonal antibody against
peptidoglycan. By contrast, a rabbit polyclonal antibody against
Clamydophyla pneumoniae provided some findings of interest. In
all seven HD patients examined, a curious curved morphological
structure immunoreacted with this antibody (Figure 8). These
curved filamentous structures of about 5–10 µm have not
been detected by our group in brain samples from patients
with other neurodegenerative diseases (Pisa et al., 2015a, 2017;
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FIGURE 5 | Analysis of corpora amylacea in Huntington’s disease brain sections by immunohistochemistry. Striatum sections from HD patients were incubated with
rabbit polyclonal antibodies against C. albicans (A), P. notatum (B–D), P. betae (E,F), chitin (G–I) and enolase (J–L) appear in green. (B,G,K) HD4; (A,C,E): HD5;
(D,H,K): HD6; (F,I,L): HD7. Nuclei were stained with DAPI (blue). Scale bar: 20 µm.
Alonso et al., 2018b). The possibility that this morphology may
correspond to a spirochete is tempered by the finding that it failed
to immunoreact with an anti-Borrelia antibody.
Identification of Bacteria in Huntington’s
Disease Brain
In an initial attempt to detect prokaryotic DNA in brain tissue
from HD patients, we used a PCR assay on DNA extracted
from frozen samples, as indicated above for the detection
of fungal DNA. First, PCR analyses were carried out using
different primers that recognize prokaryotic DNA. One set
of primers (universal) was directed to amplify a conserved
region (V3–V4) of the 16S rRNA gene, whereas the other set
amplified the IGS between the 16S and 23S rRNA genes. The
universal primers rendered a DNA fragment of similar size
independently of the bacterial species present in the sample,
whereas the IGS primers rendered different sized fragments
depending on the species detected. Interestingly, a DNA fragment
of about 400 bp was present in all samples tested from the
seven HD patients using the universal primers (Supplementary
Figure 3, panel A). Sequencing analysis identified Burkholderia
cepacia and uncultured burkholderia in most of these samples.
Curiously, after sequencing the different fragments amplified by
the IGS primers (Supplementary Figure 3, panel B), several
bacterial species were identified, including Cutibacterium acnes
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FIGURE 6 | Identification of fungal phylum order and genus by next-generation sequencing. DNA was extracted from HD brain tissue for next-generation
sequencing. Computational analyses of the sequences using QIIME classified the data into fungal phyla, order and genera. (A) Striatum tissue from seven HD brains.
(B) Frontal cortex tissue from seven HD brains. Asc: Ascomycota, Bas: Basidiomycota, Chy: Chytridiomycota.
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TABLE 1 | Most relevant fungi detected in the frontal cortex and striatum from
Huntington’s disease patients.
ST FC
Candida (2.4–10.9%) Candida (3.9–11.2%)
Ramularia (1.5–3.2%) Ramularia (1.1–3.3%)
Davidiella (11.1–69.3%) Davidiella (2.7–10.9%)
Xylaria (1.4–2.7%) Xylaria (3.49%)
Rhodotorula (2.1–26.1%) Rhodotorula (1.8–3.1%)
Malassezia (1.7–2.4%) Malassezia (1.8–15.3%)
(formerly known and Propionibacterium acne), Escherichia coli
and Streptococcus spp. (Supplementary Table 4). These findings
suggest that some species are preferentially recognized and
amplified by the PCR assay depending on the primers and the
PCR conditions. Finally, to test for the presence of spirochetes in
the CNS samples from HD patients, we employed unique primers
that detect this bacterial group. Control DNA extracted from
B. burgdorferi rendered a DNA fragment of ∼350 bp using this
assay (Supplementary Figure 3, panel C). However, no product
was detected with the DNA samples from HD patients, pointing
to the absence of spirochetes. Indeed, this finding is consistent
with the results described above showing no immunoreaction
with anti-Borrelia antibodies.
We next used NGS to better assess the bacterial species
in the HD brain samples. A great variety of bacterial species
were identified both in striatum and FC regions from the seven
patients (Supplementary Table 5). The most relevant bacteria
are listed in Table 2. Notably, the genus Burkholderia was very
prominent in some of the samples, in good agreement with
the observations obtained by PCR analysis. Also, Pseudomonas
and Acinetobacter were prominent in these patients. Indeed,
the bacterial genera found in HD differed from the most
FIGURE 8 | Prokaryotic structures in Huntington’s disease brain sections
using an anti-C. pneumoniae antibody. Different sections from HD patients
were incubated with a rabbit polyclonal antibody against C. pneumoniae
(green). DAPI staining is shown in blue. (A,C,E,F,H,J,K) striatum region;
(B,D,G,I,L) frontal cortex region; (A,B) HD1; (C,D) HD2; (E) HD3; (F,G) HD4;
(H,I) HD5; (J) HD6; (K,L) HD7. Scale bar: 5 µm.
prominent species detected in patients with Alzheimer’s disease
or amyotrophic lateral sclerosis (Alonso et al., 2018a, 2019). The
phyla and classes of the bacteria found in the striatum and FC
are shown in Figure 9. Of note, proteobacteria and the classes
gamma proteobacteria and Actinobacteria, were abundant in
HD brain tissue.
PCA of striatum and FC results from the seven HD patients
is illustrated in Figure 10, panel A. No discrimination of the
prokaryotic species identified in the two CNS regions was
detected by this analysis. Notably, when we compared the two
FIGURE 7 | Principal component analysis of fungi identified by next-generation sequencing. 3D principal component analysis scatter plots of HD and Parkinson’s
disease (PD) patients. Panel (A) shows the distribution between striatum (plots in blue) and frontal cortex (plots in red) regions of seven HD patients. Panel (B) shows
the distribution between HD patients (plots in red) and PD patients (plots in blue). The UniFrac method was used to calculate this parameter. ST, striatum; FC, frontal
cortex; MC, motor cortex; MS, mesencephalon.
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TABLE 2 | Most relevant bacteria detected in the frontal cortex and striatum from
Huntington’s disease patients.
ST FC
Pseudomonas (8.21–54.1%) Acinetobacter (13.5–69.6%)
Cutibacterium (3.8–49%) Burkholderia (49%)
E. coli (1.02–33%) Pseudomonas (15.3%)
Acinetobacter (10.6–28.8%) Cutibacterium (14.6%)
Burkholderia (7.24–17.5%) E. coli (8.5–8.9%)
CNS regions from HD with the mesencephalon and motor cortex
regions from Parkinson’s disease patients, clustering of HD and
mesencephalon from PD patients was evident. Curiously, a clear
segregation of bacteria present in the motor cortex from PD
brains was found. This finding supports the notion that the
bacterial species of the striatum and FC from HD brains are
similar to those detected in the mesencephalon from Parkinson’s
disease patients. By contrast, the prokaryotic species of the
motor cortex of Parkinson’s disease patients brains are different
(Figure 10, panel B). This result supports the idea that bacteria
present in brain microbiota in HD clearly differ from that
observed in the motor cortex in Parkinson’s disease.
DISCUSSION
The main factor that determines HD is the CAG repeat
expansion in the HTT gene, but the severity and progression
of the disease can be shaped by other modulatory genes. In
addition to HTT promoter alterations, genome-wide association
FIGURE 9 | Distribution of bacterial phyla and classes in CNS samples from Huntington’s disease patients. Computational analyses of the sequences obtained using
next-generation sequencing were carried out with QIIME. Bacterial phyla and classes obtained with this program are shown. Panel (A) shows bacterial phyla and
classes detected in striatum of HD patients. Panel (B) shows bacterial phyla and classes detected from frontel cortex of PD patients.
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FIGURE 10 | Principal component analysis of bacterial identified by next-generation sequencing. 3D principal component analysis scatter plots of HD and
Parkinson’s disease patients. Panel (A) shows the distribution between striatum (plots in blue) and frontal cortex (plots in red) regions of seven HD patients. Panel (B)
shows the distribution between HD patients (plots in red) and Parkinson’s disease patients (plots in blue). The UniFrac method was used to calculate this parameter.
ST, striatum; FC, frontal cortex; MC, motor cortex; MS, mesencephalon.
studies have highlighted a number genes mainly involved in
DNA repair as potential candidates to regulate HD (Lee et al.,
2011; Becanovic et al., 2015; Moss et al., 2017). Also, epigenetic
factors might regulate the progression and pathology of HD
(Berson et al., 2018; Sallustio et al., 2019). In this regard,
the present study is the first attempt to analyze in detail
the brain microbiota in HD patients, which might constitute
a risk factor that can contribute to the time of appearance
of clinical symptoms. Microbial infections can play a part
in the severity and progression of these symptoms. In this
regard, it is noteworthy to find some fungal genera and some
bacterial species that are more prevalent in HD as compared
with other neurodegenerative diseases. This is the case for
the genus Ramularia, which in concert with other fungi and
bacteria can lead to alterations in neural cells. Also, our
observation of a potential prokaryotic structure with a curved and
filamentous morphology is typical of HD brains. Several bacterial
genera such as Pseudomonas, Acinetobacter, and Burkholderia
are more prevalent in HD than in Alzheimer’s disease or
amyotrophic lateral sclerosis (Alonso et al., 2018b, 2019).
Therefore, the specific microbiota of HD might participate in the
neuropathology of the disease and might progressively colonize
different areas of the HD brain that are prone to infection by
some particular microbial species. This may be due to the fact
that immune cells, microglia and other neural cells that synthesize
the Huntingtin, facilitate this colonization. In addition, the
tropism of these microorganisms for some brain regions could
represent an important factor to explain the pathological findings
observed in HD. The continuous production of extracellular
enzymes (proteases, lipases, etc.) and also the synthesis of toxic
compounds by some microbes could play an important part in
the pathophysiology of HD. In this regard, mycotoxins, such
as aflatoxins, ochratoxin A and trichothecenes can provoke a
variety of cellular injuries, including the production of reactive
oxygen species and mitochondria dysfunction (Yoon et al., 2009;
Liu and Wang, 2016; Wang et al., 2017; Wu et al., 2017).
In HD and other neurodegenerative diseases, mitochondria
dysfunction and reactive oxygen species are usually detected in
the CNS (Franco-Iborra et al., 2018; Elfawy and Das, 2019). It
is therefore feasible that cellular alterations observed in patients
with these diseases could be due to the continuous production
of toxic molecules by microbes that progressively colonize the
CNS. Consistent with this proposal should be the induction of
general brain atrophy, selective tissue destruction and neural
death observed in HD.
There are several arguments against the concept that post-
mortem microbial colonization has occurred in HD patients: (1)
the intracellular and even intranuclear location of some fungal
structures indicates that infection took place in living cells. It
is well established that fungi only enter metabolically active
cells (Pacheco et al., 2007; Casadevall, 2008; Seider et al., 2014;
Munoz-Duarte et al., 2016; Nelson and Nelson, 2018). (2) The
presence of fungal antigens in CA is also consistent with the
idea that these bodies entrapped fungal proteins during their
formation over several months or years. (3) PCA demonstrates
that the brain fungal mycobiome in HD is different from that in
Parkinson’s disease. (4) Our previous studies using brain sections
from control subjects did not show the variety of fungal structures
observed in HD (Alonso et al., 2018b). Also, the putative
bacterium with a curved and filamentous morphology described
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here has not been detected in brain sections from control subjects
or in patients with other neurodegenerative diseases.
A salient clinical symptom in HD is neuroinflammation
(Crotti and Glass, 2015; Rocha et al., 2016). Indeed, microglia
and complement activation, as well as elevated levels of some
interleukins, has been detected in HD brains (Singhrao et al.,
1999; Bjorkqvist et al., 2008; Crotti et al., 2014). Moreover,
these increased levels of interleukins and tumor necrosis factor
are also found in the plasma of HD patients, even years
before the disease is diagnosed, indicating systemic inflammation
(Crotti and Glass, 2015; Politis et al., 2015). Increased
circulating levels of other cytokines and pro-inflammatory
molecules, such as C-reactive protein, are also detected in
HD (Wang et al., 2014; Rocha et al., 2016). It is possible
that the synthesis of mutated Huntingtin or the production
of necrotic cell debris together with the aberrant protein can
activate microglia and stimulate immune cells. Alternatively,
based on our present findings it might be possible that
neuroinflammation, microglia and complement activation are
provoked by microbial infection. Likewise, the existence of
infection would lead to a general stimulation of the immune
system and the consequent elevated levels of cytokines in the
plasma of these patients.
Another important characteristic in HD is the synthesis
of amyloid (Mann and Jones, 1990; Chiti and Dobson, 2006;
Porta et al., 2015; Shao et al., 2017) and it is noteworthy
that amyloid peptide forms part of the innate immune
system (Soscia et al., 2010; Kumar et al., 2016). Thus, it
is possible that the synthesis of amyloid is triggered by
microbial infection in HD. Notably, chitinase is also a biomarker
for HD and appears in high levels in the CSF of patients
(Vinther-Jensen et al., 2016). Chitinase, which is an enzyme
synthesized by astrocytes and macrophages interacts with the
polysaccharide chitin, which is a component of the fungal
cell wall (Lee et al., 2011; Bonneh-Barkay et al., 2012;
Gow et al., 2017).
Several scenarios can then be envisaged to help understand
the pathology of HD. Since the most important feature of
HD is the presence of CAG repeats in the HTT gene, it
is possible that the accumulation of aberrant Huntingtin
synthesized along several years could provoke cellular
disfunction, and finally cell death. Considering the present
findings, another possibility could be that dysfunction of
the immune system and modifications in some tissues by
mutated Huntingtin creates an environment conducive for
colonization by some microbial species. In this respect, the
initial infection by some microorganisms could also facilitate
the entry of other opportunistic fungi and/or bacteria. In
the second possibility, two alternatives can be considered.
One is that brain colonization by microorganisms has
no neuropathological effects. However, a more plausible
alternative is that these polymicrobial infections can alter
the natural physiology of neural cells. Moreover, our current
observations provide an explanation for disease in those
HD patients that do not harbor the CAG expansion repeat.
In these patients without the expansion repeat, the clinical
symptoms could be provoked by polymicrobial infections
in some brain regions. As indicated above, the expression
of mutated HTT can increase the probability for this
microbial colonization, which could also take place in some
instances even when normal Huntingtin, is synthesized.
To distinguish between the different possibilities, clinical
trials with safe anti-fungal and anti-bacterial compounds
can aid to elucidate the role played by these infections
in HD pathology.
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